Pro-inflammatory cytokine pathway

The **pro-inflammatory cytokine pathway** refers not to a single molecular target, but rather to a collection of signaling cascades mediated by a group of cytokines (such as IL-1, IL-6, TNF-α, IL-17, IFN-γ) that promote and sustain inflammation[1][3][4][6][9]. These cytokines are secreted by immune cells (e.g., Th1 cells, macrophages, dendritic cells) and act by binding to specific cytokine receptors on target cells, triggering downstream signaling pathways that activate gene expression, promote immune cell recruitment, regulate cell proliferation, and mediate host defense[1][4][6]. Dysregulation of this pathway can result in chronic inflammation, tissue damage, and a wide variety of immune-related diseases, including autoimmune disorders, cancer, and infections[4][5][7]. Therapeutic strategies currently target specific cytokines or their receptors (e.g., anti-TNF, anti-IL-6R antibodies) to modulate this pathway in disease[2][5]. Note: The "pro-inflammatory cytokine pathway" is a collective term for a group of signaling pathways rather than a discrete molecular target like a receptor or enzyme. For structured data extraction, use the names of individual cytokines (such as "Tumor necrosis factor" or "Interleukin-6 receptor") as targets, not the pathway name as the canonical target.

Other names

Proinflammatory cytokine signalingPro-inflammatory cytokine signalingPro-inflammatory cytokine cascadeCytokine storm pathway

Monoclonal antibodies or biologics block pro-inflammatory cytokine activity or their receptors (e.g., TNF inhibitors neutralize TNF-α activity; anti-IL-6R therapy blocks IL-6 mediated signaling)[2][5]. Cytokine receptor antagonists prevent ligand-receptor interaction and downstream signaling[5].